特里科斯塔丁A通过PKM2调节葡萄糖和脂质新陈代谢来影响树突细胞的功能
Xiaoyu Yang1, Lihui Men1, Yan Guo1
1Department of Pharmacology, College of Basic Medical Science, Jilin University, Changchun 130021, China.
Molecules (Basel, Switzerland)
|January 28, 2026
概括
三静素A (TSA) 通过改变其新陈代谢,保护树突细胞 (DCs) 在心肌梗塞 (MI) 期间免受损伤. TSA通过Pyruvate kinase M2 (PKM2) 调节葡萄糖和脂质通路,增强免疫保护.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
- 细胞生物学 细胞生物学
背景情况:
- 树突细胞 (DCs) 对于对抗心肌梗塞 (MI) 的免疫反应至关重要.
- 细胞代谢在MI等缺血性疾病期间显著影响DC功能.
- 了解DC中的代谢变化对于开发新型MI疗法至关重要.
研究的目的:
- 在缺氧-葡萄糖 (OGD) 条件下研究DCs的代谢变化.
- 确定Pyruvate kinase M2 (PKM2) 在OGD期间DC代谢中的作用.
- 评估Trichostatin A (TSA) 在MI的背景下调节DC代谢和功能的治疗潜力.
主要方法:
- 生物信息学分析
- 定量实时PCR (qPCR) 是一种实时PCR技术.
- 西方涂抹是指西方涂抹.
- 免疫光显微镜的使用方法
- 在MTT测试中,测量MTT.
- 心声回声扫描 (Echocardiography) 是一种心声回声扫描.
- 三四化 (TTC) 染色方式
- 流动细胞计量流动细胞计量
主要成果:
- 在OGD条件下,DC代谢发生显著变化.
- 在OGD期间,pyruvate kinase M2 (PKM2) 表达在DC上升调节.
- 三素A (TSA) 治疗减轻了DC中OGD诱导的细胞损伤.
- 在DC中,TSA增强糖解,抑制脂肪酸合成/氧化.
- 由TSA和OGD诱导的代谢变化是由PKM2调节的,PKM2通过二聚体的形成来调节葡萄糖和脂质代谢.
结论:
- 代谢重编程是心脏病发作期间DC功能的一个关键因素.
- 在缺血性压力下,PKM2在DC中的代谢变化中起着关键作用.
- 通过PKM2调节DC代谢,从而增强免疫保护,TSA证明了对MI的治疗潜力.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


